Diabetes Care, Vol 20, Issue 8 1287-1289, Copyright © 1997 by American Diabetes Association

ARTICLES

Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin

P Ebeling, PA Jansson, U Smith, C Lalli, GB Bolli and VA Koivisto
Department of Medicine, Helsinki University Hospital, Finland.

OBJECTIVE: To examine whether overall glycemic control can be improved with insulin lispro by adjustment of the basal insulin regimen without an increased risk of hypoglycemia. RESEARCH DESIGN AND METHODS: A 5-month open study was performed in 66 IDDM patients after they had been transferred from human regular insulin to insulin lispro as a premeal therapy. The premeal and basal insulin regimens were adjusted according to self-monitoring of blood glucose during the visits at 2-week to 1-month intervals. Diurnal glucose profile, hypoglycemic events, HbA1c, and patient satisfaction were evaluated. RESULTS: The mean daily glucose level decreased from 9.2 +/- 0.2 to 8.4 +/- 0.2 mmol/l (P = 0.001) and HbA1c decreased from 8.8 +/- 0.1 to 8.0 +/- 0.1% (P < 0.001) (mean +/- SD). The number of daily NPH injections increased from 1.4 +/- 0.1 at baseline to 3.1 +/- 0.1 at the end of the study. Total daily insulin dose increased by 3 U (7%) because of an 8-U (43%) rise in basal insulin, whereas premeal insulin dose decreased by 5 U (20%). The number of hypoglycemic episodes did not change during the study. Of the patients, 86% considered insulin lispro equal or better than human regular insulin. CONCLUSIONS: Although the study was open, the date suggest that the appropriate combination of insulin lispro and basal insulin can improve postmeal hyperglycemia, HbA1c, and treatment satisfaction without increasing the risk of hypoglycemia.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Rossetti, S. Pampanelli, C. Fanelli, F. Porcellati, E. Costa, E. Torlone, L. Scionti, and G. B. Bolli Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime Diabetes Care, May 1, 2003; 26(5): 1490 - 1496. [Abstract] [Full Text] [PDF]

				T. Lindstrom, C. A. Hedman, and H. J. Arnqvist Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs Diabetes Care, June 1, 2002; 25(6): 1049 - 1054. [Abstract] [Full Text] [PDF]

				A. M.E. Stades, J. B.L. Hoekstra, I. van den Tweel, D. W. Erkelens, and F. Holleman Additional Lunchtime Basal Insulin During Insulin Lispro Intensive Therapy in a Randomized, Multicenter, Crossover Study in Adults : A real-life design Diabetes Care, April 1, 2002; 25(4): 712 - 717. [Abstract] [Full Text] [PDF]

				J. D. Meece and R. K. Campbell Insulin Lispro Update The Diabetes Educator, March 1, 2002; 28(2): 269 - 277. [Abstract] [PDF]

				L. C. Deeb, J. H. Holcombe, R. Brunelle, S. Zalani, S. Brink, M. Jenner, H. Kitson, K. Perlman, and M. Spencer Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes Pediatrics, November 1, 2001; 108(5): 1175 - 1179. [Abstract] [Full Text] [PDF]

				B. Guerci, L. Meyer, A. Sallé, A. Charrié, B. Dousset, O. Ziegler, and P. Drouin Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2673 - 2678. [Abstract] [Full Text]

				R. K. Campbell, D. A. Sclar, L. M. Robison, J. K. Stowers, J. C. Ferguson, B. S. Trippe, and D. M. Kayne Impact on Clinical. Status and Quality of Life of Switching From Regular Insulin to Insulin Lispro Among Patients Using Insulin Pumps The Diabetes Educator, January 1, 1998; 24(1): 95 - 99. [PDF]